Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

Abstract

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs) (crizotinib then alectinib), as her imaging findings and clinical symptoms significantly improved. At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib. The adverse effects were manageable. The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion.

Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes

“…To comprehensively study the discovery of IGR events in lung cancer, we searched PubMed publications and conference abstracts for reports of intergenic fusion cases. By June 2021, a total of 74 IGR cases were identified by DNA-based NGS in 19 single-case reports or cohort studies 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ( Supplementary Table S3 , available at https://doi.org/10.1016/j.esmoop.2022.100405 ). Fifty-three of those cases were ALK fusions.…”